CXCL13 expression has also been reported to be upregulated by interleukin 6 (IL-6) through an unknown mechanism, which may be significant in BM-PCa, as IL-6 levels are observed to be higher in PCa patients with bone metastases (128, 132, 133). This evidence concerns the gene IL6 and posterior cortical atrophy.